Document is current
Any future updates will be listed below
-
Authors
Rehues, Pere
Girona, Josefa
Guardiola, Montse
Ozcariz, Enrique
Amigó, Núria
Rosales, Roser
Esteban, Yaiza
Banús, Helena
Gavaldà-Alsina, Gemma
González-Lleó, Ana
Rojo-Martínez, Gemma
Ribalta, Josep
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI21/01294)
Instituto de Salud Carlos III (PI21/01294)
Instituto de Salud Carlos III (PI21/01294)
Instituto de Salud Carlos III (PI21/01294)
Instituto de Salud Carlos III (PI21/01294)
Instituto de Salud Carlos III (PI21/01294)
European Regional Development Fund
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
Cerca Programme, Generalitat de Catalunya, Spain
Ministerio de Universidades (FPU19/04610)
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 29 November 2024
First Online: 4 December 2024
Declarations
:
: The research was carried out in accordance with the Declaration of Helsinki (WHO 2011) of the World Medical Association. Written informed consent was obtained from all the participants. The study was approved by the Ethics and Clinical Investigation Committee of the Hospital Regional Universitario de Málaga (Malaga, Spain) in addition to other regional ethics and clinical investigation committees all over Spain.
: Not applicable.
: N.A. is a stock owner of Biosfer Teslab and has a patent on the method for lipoprotein profiling described in the present manuscript.
